Search results
Welcome Stadium a welcome site for RV thrower Ethan Lyon as the state meet moves from OSU
The Marion Star via Yahoo Sports· 4 days ago...Friday 7:20 p.m. ● Northmor's Ryan Lehman, David Blunk, Griffin Healea, Levi Hunter: D-III boys...
No Survival Advantage With Sacituzumab Over Chemo in Previously Treated NSCLC
MedPage Today· 1 day agoResults are 'disappointing as we need better therapies in the refractory space,' expert says
Roche’s Sabry retires; Duchenne drug fails confirmatory test
BioPharma Dive via Yahoo Finance· 6 days agoThe veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative...
7 Biotech Stocks to Put on Your Breakthrough Radar
InvestorPlace via Yahoo Finance· 7 days agoFor those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower....
Cell therapy reckoning: How to get cell therapies flying off-the-shelf
FierceBiotech· 3 days agoThis story is the final part of a four-part series about cell therapy created by the Fierce Biotech...
STAMP Inhibitor Tops Imatinib, Second-Gen TKIs for Newly Diagnosed CML
MedPage Today· 3 days agoThe STAMP inhibitor asciminib (Scemblix) had a statistically superior response rate compared with...
Biotech faces a reckoning: ‘We've lost our luster in cell therapies’
FierceBiotech· 5 days agoThis story is the first part in a four-part series about cell therapy, created by the Fierce Biotech...
Cell therapy reckoning: Pivot to autoimmune leaves unmet need in oncology
FierceBiotech· 4 days agoThis story is part 2 in a four-part series about cell therapy created by the Fierce Biotech team....
G1 Therapeutics seeks partner to advance cancer treatment - Triangle Business Journal
The Business Journals· 4 days agoA biopharmaceutical company in Research Triangle Park is looking for a partner to advance one of its...
AstraZeneca-Daiichi's Enhertu follow-up Dato-DXd unable to prove overall survival benefit in phase 3
FierceBiotech· 6 days agoDaiichi Sankyo and antibody-drug conjugate (ADC) partner AstraZeneca have already filed their...